JPM
JPMorgan Chase & Co.
JPM's fundamentals are strong, but it looks expensive: trading at 14x earnings, above its usual 12x. Analysts expect earnings growth.
NMR
Nomura Holdings, Inc.
There isn't enough reported data to score NMR yet.
JPM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
JPM's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like JPM.
NMR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| N/A | |
| N/A |
NMR's profitability is currently healthy. There isn't enough data to rate its revenue. Free cash flow and net leverage aren't meaningful measures for financial services companies like NMR.
JPM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $231 | -33% |
| Fair | 12x | $287 | -16% |
| Current | 14x | $343 | — |
| Forward | 14x | $343 | — |
| Expensive | 15x | $361 | +5.2% |
Historical ranges are pointers, not guarantees.
JPM has the edge over NMR in the historical PE scenario, which offers more potential upside but is not a forecast.
NMR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.9x | $5.90 | -38% |
| Fair | 12x | $8.70 | -9% |
| Current | 13x | $9.56 | — |
| Expensive | 18x | $13.82 | +45% |
Historical ranges are pointers, not guarantees.
NMR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
JPM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
JPM has the edge over NMR on the outlook, with more favorable earnings and profitability expectations.
NMR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| High |
Analysts expect NMR's revenue to grow, but its profitability to weaken.
JPM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.99 | +4.8% |
| Q3 2026 | $23.85 | +18% |
| Q2 2026 | $23.35 | +20% |
| Q1 2026 | $20.89 | +2.5% |
| Q4 2025 | $20.02 | +1.4% |
| Q3 2025 | $20.20 | +12% |
| Q2 2025 | $19.50 | +8.7% |
| Q1 2025 | $20.38 | +23% |
| Q4 2024 | $19.75 | +22% |
JPM's earnings per share have climbed steadily: $23.85 over the past year, up 18% from the year before, and higher year over year for 15 quarters in a row.
NMR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2026 | $0.75 | +7.1% |
| Q3 2025 | $0.76 | +36% |
| Q1 2025 | $0.70 | +112% |
| Q3 2024 | $0.56 | +107% |
| Q1 2024 | $0.33 | +74% |
| Q3 2023 | $0.27 | +23% |
| Q1 2023 | $0.19 | -32% |
| Q3 2022 | $0.22 | +$0.23 |
NMR has the edge over JPM in the latest year-over-year earnings comparison.
JPM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2B | +8.1% |
| Q2 2026 | $57.3B | +28% |
| Q1 2026 | $49.8B | +10% |
| Q4 2025 | $45.8B | +7.1% |
| Q3 2025 | $46.4B | +8.8% |
| Q2 2025 | $44.9B | -11% |
| Q1 2025 | $45.3B | +8.1% |
| Q4 2024 | $42.8B | +11% |
JPM's revenue has grown year over year for five quarters in a row: $50.2B last quarter, up 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -0.2 points |
| Q2 2026 | 48% | +7.3 points |
| Q1 2026 | 41% | +0.5 points |
| Q4 2025 | 37% | -3.2 points |
| Q3 2025 | 40% | +0.6 points |
| Q2 2025 | 41% | -6 points |
| Q1 2025 | 41% | -0.6 points |
| Q4 2024 | 41% | +11 points |
JPM's operating margin was 40% last quarter, about level with the same quarter a year ago.
NMR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $7.1B | +18% |
| Q3 2025 | $6.5B | +11% |
| Q1 2025 | $6B | +13% |
| Q3 2024 | $5.9B | +31% |
| Q1 2024 | $5.3B | +18% |
| Q3 2023 | $4.5B | +16% |
| Q1 2023 | $4.5B | +3.9% |
| Q3 2022 | $3.9B | -8.2% |
NMR has the edge over JPM in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | 21% | -0.3 points |
| Q3 2025 | 28% | +14 points |
| Q1 2025 | 25% | +6.3 points |
| Q3 2024 | 25% | +18 points |
| Q1 2024 | 21% | +2.6 points |
| Q3 2023 | 15% | +0.9 points |
| Q1 2023 | 18% | +26 points |
| Q3 2022 | 7.8% | -24 points |
NMR's operating margin was 21% last quarter, about level with the same quarter a year ago.
JPM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.2B | +$78.4B |
| Q2 2026 | -$25.3B | -186% |
| Q1 2026 | -$211.8B | +$40.1B |
| Q4 2025 | $119.7B | -19% |
| Q3 2025 | -$45.2B | +$28.9B |
| Q2 2025 | $29.5B | -23% |
| Q1 2025 | -$251.8B | -$97.7B |
| Q4 2024 | $147.8B | +145% |
JPM's free cash flow was −$84.2B over the past year, against −$120B the year before. Free cash flow isn't a meaningful measure for financial services companies like JPM.
NMR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$12.7B | -$10.1B |
| Q3 2025 | $5.2B | +$8B |
| Q1 2025 | -$2.6B | -$1.6B |
| Q3 2024 | -$2.8B | -420% |
| Q1 2024 | -$968.3M | -$27.3M |
| Q3 2023 | $885.9M | +$5.4B |
| Q1 2023 | -$941M | +$6.6B |
| Q3 2022 | -$4.5B | -$2.8B |
NMR's free cash flow was −$12.9B over the past year, against −$5.5B the year before. Free cash flow isn't a meaningful measure for financial services companies like NMR.
JPM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -11.2M shares |
| 1 year | -3.1% | -84.6M shares |
| 3 years | -8.5% | -249M shares |
| 5 years | -11% | -322M shares |
| Available history | -17% | -547M shares |
JPM has 2.7B diluted shares, down 3.1% from a year ago, with $24.5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1B |
| Q2 2026 | $6.8B |
| Q1 2026 | $8.3B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.3B |
| Q2 2025 | $7.5B |
| Q1 2025 | $7.5B |
| Q4 2024 | $4.3B |
JPM spent $24.5B buying back its own shares over the past year, down 11% from the year before.
NMR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -9.6% | -325M shares |
| 1 year | -14% | -498M shares |
| 3 years | -20% | -781M shares |
NMR has the edge over JPM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2026 | $260.1M |
| Q3 2025 | $376.1M |
| Q1 2025 | $50,144 |
| Q3 2024 | $369.8M |
| Q1 2024 | $257.1M |
| Q3 2023 | $125.4M |
| Q1 2023 | $9.5M |
| Q3 2022 | $145.5M |
JPM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
JPM's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like JPM.
NMR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 21.7x | High |
| Q3 2025 | 16.5x | High |
| Q1 2025 | 18.8x | High |
| Q3 2024 | 19.0x | High |
| Q1 2024 | 26.8x | High |
| Q3 2023 | 28.2x | High |
| Q1 2023 | 31.5x | High |
| Q3 2022 | 32.4x | High |
NMR's net debt is more than 20 years of its operating earnings (EBITDA), down from more than 20 years a year ago. Net leverage isn't a meaningful measure for financial services companies like NMR.
JPM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.5 | Neutral |
JPM's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
NMR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.8 | Neutral |
| Stochastic | 26.2 | Neutral |
NMR's weekly RSI is 53 (neutral) and its Stochastic is 26 (neutral).
JPM PE vs Financial Services Sector
| Metric | JPM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 10% above |
| PE % | 76 | 63 | 13 pts above |
JPM is trading at 14x earnings, a 10% premium to the Financial Services sector's median of 13x.
NMR PE vs Financial Services Sector
| Metric | NMR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 13x | 1.5% below |
| PE % | 59 | 63 | 4 pts below |
NMR has the edge over JPM on valuation relative to its sector.
JPM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.8 | 1.8% above |
| 20 week MA | $345.3 | 0.7% below |
| 50 week MA | $323.2 | 6.1% above |
| 100 week MA | $298.9 | 15% above |
| 200 week MA | $236.6 | 45% above |
JPM's trend is mixed: it's above four of its five weekly moving averages, and 45% above its 200-week average.
NMR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.49 | 0.7% above |
| 20 week MA | $9.75 | 1.9% below |
| 50 week MA | $8.94 | 6.9% above |
| 100 week MA | $7.73 | 24% above |
| 200 week MA | $6.28 | 52% above |
NMR's trend is mixed: it's above four of its five weekly moving averages, and 52% above its 200-week average.
JPM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.1 | $124.5 | -11% |
| 2021 | $124.5 | $157.3 | +26% |
| 2022 | $157.3 | $131.3 | -17% |
| 2023 | $131.3 | $170.1 | +30% |
| 2024 | $170.1 | $241.2 | +42% |
| 2025 | $241.2 | $327.9 | +36% |
| 2026 YTD | $327.9 | $342.8 | +4.5% |
JPM has finished higher in four of the last six years. It's up 4.5% so far in 2026.
NMR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.12 | $5.22 | +2% |
| 2021 | $5.22 | $4.43 | -15% |
| 2022 | $4.43 | $3.68 | -17% |
| 2023 | $3.68 | $4.51 | +23% |
| 2024 | $4.51 | $5.86 | +30% |
| 2025 | $5.86 | $8.41 | +44% |
| 2026 YTD | $8.41 | $9.56 | +14% |
NMR has the edge over JPM on returns for 2026, with the stronger performance.